You are here: Industry Insights > obesity

News List

Outlook for the Development of Weight-loss Drugs in 2025 Krebs Qin
January 23, 2025
This article focuses on the challenges and opportunities for weight-loss drug development in 2025 after semaglutide and tirzepatide's market dominance. It covers GLP-1 drugs' potential in organ protection, new drug mechanisms, and pipeline products.
Gut Hormone-Based Pharmacotherapies for Obesity Neeta Ratanghayra
April 28, 2024
The history of pharmacotherapy for obesity is marked by a series of promising drugs that were withdrawn due to safety concerns.
NMN: A Star Drug on the Way toward a “Miracle Drug” PharmaSources/Yuntian
January 28, 2021
As a new star API, NMN, i.e., nicotinamide mononucleotide, is a reaction product of nicotinamide phosphoribosyltransferase (NAMPT).
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update PharmaSources
January 22, 2025
Ascletis announces positive topline results from its U.S. SAD study of ASC30 oral tablet in obese patients, showing good PK, safety and potential for best - in - class status.
NICE approves Wegovy™ (semaglutide) for obesity EuropeanPharmaceuticalReview
February 11, 2022
New draft guidance means thousands of obese Brits could benefit from Novo Nordisk’s Wegovy™ (semaglutide), a drug shown to improve weight loss.
New management: Promising drug for people living with obesity pharmatimes
February 08, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%.
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH prnasia
December 29, 2021
EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its wholly owned US subsidiary...
Many Overweight Kids Already Have Hardened Arteries, Diabetes drugs.com
December 20, 2021
If your children struggle with their weight, new research suggests they may also suffer from diseases once seen only in adults.
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity prnasia
November 08, 2021
Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period.
Rates of Obesity, Weight Gain Up for Transmasculine Individuals drugs
August 26, 2021
Transmasculine individuals have greater rates of obesity and increased weight gain before and during hormone therapy compared with transfeminine individuals, according to a study published online Aug. 16 in the International Journal of Obesity.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page